Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids

Fertility and Sterility

Volumn 89, Issue 2, 2008, Pages 421-428

  Morris, Edward Patrick ^a   Rymer, Janice ^b   Robinson, Jill ^b   Fogelman, Ignac ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

add back therapy; GnRH agonists; tibolone; Uterine fibroids

Indexed keywords

GONADORELIN; GOSERELIN; PLACEBO; TIBOLONE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENORRHAGIA; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UTERUS MYOMA; VAGINA BLEEDING;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BONE AND BONES; BONE DENSITY; CHEMOTHERAPY, ADJUVANT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEIOMYOMA; MIDDLE AGED; NORPREGNENES; PATIENT COMPLIANCE; PLACEBOS; TREATMENT OUTCOME; UTERINE HEMORRHAGE; UTERINE NEOPLASMS;

EID: 38949179180     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.02.064     Document Type: Article

References (34)

1. Lethaby A., and Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Clin Evid 14 (2005 Dec) 2264-2282
2. van Leusden H.A., and Dogterom A.A. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH. Gynecol Endocrinol 2 (1988) 45-51
3. Matta W.H., Stabile I., Shaw R.W., and Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 49 (1988) 1083-1085
4. Hackenberg R., Gesenhues T., Deichert U., Duda V., Schmidt-Rhode P., and Schulz K.D. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month. Eur J Obstet Gynecol Reprod Biol 45 (1992) 125-129
5. Maheux R., and Lemay A. Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy. Br J Obstet Gynaecol 99 (1992) 13-17
6. Friedman A.J., Hoffman D.I., Comite F., Browneller R.W., and Miller J.D. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 77 (1991) 720-725
7. West C.P., Lumsden M.A., Lawson S., Williamson J., and Baird D.T. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 48 (1987) 45-51
8. Maheux R., Lemay A., Blanchet P., Friede J., and Pratt X. Maintained reduction of uterine leimyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 6 (1991) 500-505
9. Barbieri R.L. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 106 (1992) 740-745
10. van de Viers J. Pharmacological studies with ORG OD14. Maturitas 1 Suppl (1987) 15-24
11. Tax L., Goorissen E.M., and Kicovic P.M. Clinical profile of Org OD 14. Maturitas 1 Suppl (1987) 3-13
12. Palomba S., Affinito P., Tommaselli G.A., and Nappi C. A clinical trial of the effects of tibolone administered with gonadotrophin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 70 (1998) 111-118
13. Palomba S., Affinito P., Di Carlo C., Bifulco G., and Nappi C. Long-term administration of tibolone plus gonadotrophin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass and lipid profiles. Fertil Steril 72 (1999) 889-895
14. West C.P., Lumsden M.A., Hillier H., Sweeting V., and Baird D.T. Potential role for medroxyprogesterone acetate as an adjunct to goserelin in the medical management of uterine fibroids. Hum Reprod 7 (1992) 328-332
15. Howell R., Edmonds D.K., Dowsett M., Crook D., Lees B., and Stevenson J. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 64 (1995) 474-481
16. Kiesel L., Schweppe K.W., Sillem M., and Siebzehnrubl E. Should add-back therapy be deferred for optimal results?. Br J Obstet Gynaecol 103 S14 (1996) 15-17
17. Greene J.G. A factor analytic study of climacteric symptoms. J Psychosom Res 20 (1976) 425-430
18. Lindsay P.C., Shaw R.W., Bennink H.J., and Kicovic P. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotrophin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 65 (1996) 342-348
19. Fogelman I., Fentiman I., Hamed H., Studd J., and Leather A. Goserelin (Zoladex) and the skeleton. Br J Obstet Gynaecol 101 S10 (1994) 19-23
20. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 276 (1996) 1389-1396
21. Christiansen C., and Riis B.J. Hormonal replacement therapy and the skeletal system. Maturitas 12 (1990) 247-257
22. Moghissi K.S., Schlaff W.D., Olive D.O., Skinner M.A., and Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 69 (1998) 1056-1062
23. Revilla R., Revilla M., Hernandez E.R., Villa L.F., Varela L., and Rico H. Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered. Maturitas 22 (1995) 145-150
24. Paoletti A.M., Serra G.G., Cagnacci A., Vacca A.M., Guerriero S., Jones R., et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 65 (1996) 707-710
25. Taga M., and Minaguchi H. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, naferelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 75 (1996) 162-165
26. Moore R.A. Livial: a review of clinical studies. Br J Obstet Gynaecol 106 (1999) 1-21
27. Rymer J.M. The effects of tibolone. Gynecol Endocrinol 12 (1998) 213-220
28. MacLennan A.H., Broadbent J.L., Lester S., and Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 4 (2004) CD002978
29. Pickersgill A. GnRH analogues and add-back therapy: is there a perfect combination?. Br J Obstet Gynaecol 105 (1998) 475-485
30. Friedman A.J., Daly M., Juneau-Norcross M., Rein M.S., Fine C., Gleason R., and Leboff M. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76 (1993) 1439-1445
31. Rymer J., Fogelman I., and Chapman M. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 101 (1994) 53-56
32. Hammar M., Christau S., Nathorst-Boos J., Rud T., and Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in posmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 105 (1998) 904-911
33. Morris E.P., Wilson P.O.G., Robinson J., and Rymer J.M. Long term effects of tibolone on the genital tract. Br J Obstet Gynaecol 106 (1999) 954-959
34. Gocmen A., Kara I.H., and Karaca M. The effects of add-back therapy with tibolone on myoma uteri. Clin Exp Obstet Gynecol 29 (2002) 222-224